Market closed

NeoGenomics/$NEO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About NeoGenomics

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Ticker

$NEO
Sector
Health Care
Trading on
NASDAQ

Industry

Health Care Providers & Services
Headquarters
Fort Myers, United States

Employees

2,100
Website
www.neogenomics.com

NeoGenomics Metrics

BasicAdvanced
$1.6B
-
-$0.62
1.18
-

$1.6B

1.18

$19.12

$12.13

839K

1.991

1.819

44.277

66.754

-10.83%

-2.72%

-8.38%

2.478

1.78

43.24

-74.183

12.06%

-20.17%

9.95%

15.14%

What the Analysts think about NeoGenomics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for NeoGenomics stock.

NeoGenomics Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

NeoGenomics Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

NeoGenomics News

AllArticlesVideos
NeoGenomics Announces Chief Executive Officer Succession

NeoGenomics Announces Chief Executive Officer Succession

Business Wire·5 days ago
NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

Business Wire·1 month ago
ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research

ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research

Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NEO

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for NeoGenomics stock?

NeoGenomics (NEO) has a market cap of $1.6B as of January 15, 2025.

What is the P/E ratio for NeoGenomics stock?

The price to earnings (P/E) ratio for NeoGenomics (NEO) stock is 0 as of January 15, 2025.

Does NeoGenomics stock pay dividends?

No, NeoGenomics (NEO) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next NeoGenomics dividend payment date?

NeoGenomics (NEO) stock does not pay dividends to its shareholders.

What is the beta indicator for NeoGenomics?

NeoGenomics (NEO) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.